Vera Therapeutics (VERA) Shares Outstanding (Weighted Average) (2020 - 2026)

Vera Therapeutics (VERA) has 7 years of Shares Outstanding (Weighted Average) data on file, last reported at $71.5 million in Q1 2026.

• For the quarter ending Q1 2026, Shares Outstanding (Weighted Average) rose 12.26% year-over-year to $71.5 million; the trailing twelve-month figure through Mar 2026 stood at $71.5 million (up 12.26% YoY), and the FY2025 full-year result was $64.2 million, up 16.1% from the prior year.
• Shares Outstanding (Weighted Average) for Q1 2026 stood at $71.5 million, up from $64.2 million in the prior quarter.
• Across five years, Shares Outstanding (Weighted Average) topped out at $71.5 million in Q1 2026 and bottomed at $24.2 million in Q1 2022.
• The 5-year median for Shares Outstanding (Weighted Average) is $51.0 million (2024), against an average of $47.8 million.
• The widest annual swing landed in 2022, when Shares Outstanding (Weighted Average) jumped 6186.25%; it then increased 12.26% in 2026.
• A 5-year view of Shares Outstanding (Weighted Average) shows it stood at $26.6 million in 2022, then soared by 60.73% to $42.7 million in 2023, then climbed by 29.55% to $55.3 million in 2024, then rose by 16.1% to $64.2 million in 2025, then grew by 11.28% to $71.5 million in 2026.
• The last three Shares Outstanding (Weighted Average) figures came in at $71.5 million (Q1 2026), $64.2 million (Q4 2025), and $63.8 million (Q3 2025), per Business Quant data.

Peer Comparison